Yvonne Saenger Gives a Rundown of Immunotherapy Agents for Melanoma

Yvonne Saenger, MD, Director of Melanoma Immunotherapy at Columbia University, talks about the immunotherapy agents currently available for melanoma.

Along with ipulimimab, pembrolizimab and nivolumab prolonging survival in patients with melanoma, she discusses the oncolytic virus, a novel therapy using a herpes virus that attacks tumor cells preferentially.